Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Still Waiting For Infectious Disease Strategy To Move The Needle

Arexvy Set To Lead RSV Field, But Investors Want More

Executive Summary

Ongoing Zantac litigation continues to cloud GSK’s share price, but it hopes a stream of infectious disease readouts will sway investor sentiment as it prepares for Arexvy’s launch.

You may also be interested in...

GSK Points To Merck’s Gardasil Success In Deal With Zhifei For Shingrix

The British drug maker hopes the partnership for the Chinese market will accelerate its efforts to reach its goal of £4bn or more in sales of Shingrix by 2026.

GSK And Pfizer RSV Vaccines Get US Recommendation – But Big Decisions On Pricing Yet To Come

GSK and Pfizer have both raised their price ranges based on longer-term efficacy data for their RSV vaccines, but Pfizer may choose to undercut on price in order to win market share against its rival’s more favorable data.

Corbus And Janux Lead Q1’s Small-Cap Winners

Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts